NCT00027638

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

Phase II Trial Of Thalidomide In Patients With Low Grade Neuroendocrine Tumors (Carcinoid and Islet Cell Cancers)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: —
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have metastatic neuroendocrine tumors.

Detailed description

OBJECTIVES: * Determine the safety and efficacy of thalidomide in patients with metastatic low-grade neuroendocrine tumors. OUTLINE: Patients receive oral thalidomide once daily on weeks 1-8. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.

Conditions

• Gastrointestinal Carcinoid Tumor
• Islet Cell Tumor
• Lung Cancer
• Neoplastic Syndrome

Interventions

Type	Name	Description
DRUG	thalidomide

Timeline

• Start date: 2001-03-01
• Primary completion: 2003-12-01
• Completion: 2003-12-01
• First posted: 2003-01-27
• Last updated: 2013-06-18

Locations

1 site across 1 country: United States